Skip to main content
BOTANIX PHARMACEUTICALS LTD logo

BOTANIX PHARMACEUTICALS LTD — Investor Relations & Filings

Ticker · BOT ISIN · AU000000BOT2 ASX Manufacturing
Open in API
Filings indexed 1,209 across all filing types
Latest filing 2023-04-27 Interim / Quarterly Rep…
Country AU Australia
Listing ASX BOT

About BOTANIX PHARMACEUTICALS LTD

https://botanixpharma.com/

Botanix Pharmaceuticals Ltd is a clinical-stage pharmaceutical company focused on the development and commercialization of novel topical treatments for serious skin conditions. The company utilizes its proprietary Permetrex™ skin delivery technology, which is designed to improve the delivery of active ingredients through the skin. Its primary product, Sofdra™ (sofpironium bromide), is an FDA-approved prescription topical gel for the treatment of primary axillary hyperhidrosis. The company's research and development pipeline also includes clinical-stage candidates for the treatment of acne, rosacea, and atopic dermatitis. Botanix aims to address significant unmet medical needs in dermatology by providing innovative therapeutic solutions with enhanced safety and efficacy profiles.

Recent filings

Filing Released Lang Actions
March 2023 Quarterly Activities Report and Appendix 4C 9 pages 369.9KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Botanix Pharmaceuticals Quarterly Activity Report and 4C Quarterly Cash Flow Report' for the quarter ended 31 March 2023. It contains detailed financial data including cash flow statements, operating activities, investing activities, and financing activities. It also discusses operational highlights, FDA review updates, capital raising activities, and pipeline product progress. The presence of the Appendix 4C quarterly cash flow report, which is a regulatory requirement for Australian listed entities, confirms this is a quarterly report with substantive financial data and analysis. The document is approximately 15,000 characters long, indicating it is a full report rather than a brief announcement or certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR).
2023-04-27 English
Change in substantial holding from IFL 3 pages 115.2KB
Major Shareholding Notification Classification · 100% confidence The document is titled 'Form 604 Corporations Act 2001 Section 671B Notice of change of interests of substantial holder' and details changes in voting power and shareholdings of a substantial holder in Botanix Pharmaceuticals Ltd. It lists previous and present voting power, changes in relevant interests, and details of associates. This is a notification of changes in significant share ownership levels, which matches the definition of Major Shareholding Notification (MRQ). The document is about shareholding changes, not about financial results, management, or other report types. Therefore, the correct classification is MRQ with high confidence.
2023-04-17 English
Company Secretary Change 2 pages 191.2KB
Board/Management Information Classification · 100% confidence The document is an announcement dated 17 April 2023 regarding a change in the Company Secretary of Botanix Pharmaceuticals Limited. It details the appointment of Ms. Susan Park as the new Company Secretary and the stepping down of Mr. Simon Robertson. The content focuses on management personnel changes and does not contain financial data, audit information, or regulatory filings. There is no indication of financial results, reports, or voting outcomes. Therefore, this document fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management.
2023-04-16 English
Application for quotation of securities - BOT 6 pages 27.6KB
Capital/Financing Update Classification · 100% confidence The document is an application for quotation of securities on the ASX by Botanix Pharmaceuticals Ltd. It details the number and type of securities to be quoted, issue dates, and distribution schedules. It references a previous Appendix 3B announcement related to the securities issuance. The content focuses on the listing and quotation of new shares following a capital raising event. There are no financial statements, earnings data, management discussion, or regulatory certifications. This is a clear announcement related to capital structure changes and securities issuance, fitting the Capital/Financing Update category.
2023-04-12 English
Application for quotation of securities - BOT 6 pages 27.7KB
Share Issue/Capital Change Classification · 100% confidence The document is an application for quotation of securities on the ASX, detailing the issuance and conversion of options into ordinary fully paid shares. It includes specifics about the number of securities, issue dates, and whether the securities rank equally with existing ones. This type of document is a formal announcement related to capital changes, specifically the issuance and quotation of new shares resulting from option exercises. It is not a financial report, earnings release, or management discussion. Therefore, it fits the category of Share Issue/Capital Change (SHA). The document length and content confirm it is not merely an announcement of a report but a substantive filing about capital changes.
2023-04-12 English
Notice under Section 708A(5)(e) of the Corporations Act 2 pages 160.0KB
Capital/Financing Update Classification · 95% confidence The document is a notice under Section 708A(5)(e) of the Corporations Act, which relates to the issuance of securities without disclosure under Part 6D.2 of the Corporations Act. It provides details about the securities issued (ordinary shares), the date of issue, and compliance statements. The document is an announcement notifying the market and investors about the issue of shares, not a full financial report or detailed financial data. It does not contain financial statements or management discussion but is a regulatory announcement about capital raising. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is 4716 characters, which is consistent with a detailed announcement but not a full report. Confidence is high given the clear reference to securities issuance and compliance under the Corporations Act.
2023-04-12 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.